Goldman Sachs reported about $144 million in XRP exchange-traded fund holdings in its latest quarterly filing, up from $87.4 million three months earlier, even as the token trades below $1 after a year-long slide.
The Nov. 16 filing, covering positions as of Sept. 30, lists stakes in five spot XRP funds. Franklin Templeton’s vehicle is the largest at roughly 2.95 million shares worth $47.8 million, followed by Bitwise at $38.4 million, Canary Capital at $33.3 million, Grayscale at $14.5 million and 21Shares at about $10.1 million.
Share counts show the direction of travel more clearly than dollar totals, which also move with price. Goldman added 98,642 Bitwise shares and 125,904 Grayscale shares between June and September. The filing does not disclose intent, and 13F reports omit short positions, so the figures cannot establish the bank’s net exposure to XRP.
Other institutions report different approaches. Bank of America held 13,260 shares of the futures-based Volatility Shares XRP ETF, unchanged from June. Intesa Sanpaolo disclosed 712,319 Grayscale XRP ETF shares valued at about $20.5 million, plus 402,750 Bitwise shares worth $6.7 million.
The backdrop is ugly. XRP began 2026 near $1.84 and has spent November under a dollar. XRP ETFs recorded $10.4 million in outflows earlier this month, evidence that demand for the wrappers can fall even while banks keep positions on their books.
Fund shares are not coins. Banks may hold ETF units for market making, liquidity provision, hedging or client orders, and the filing says nothing about which. Read plainly, though, a single 13F showing five separate funds is a measure of how far the regulated route into XRP has broadened since the first spot products listed, and that the largest US broker-dealers are willing to carry the exposure through a drawdown.
That willingness has limits. The reported values are marks from the end of September, when XRP was higher; a fourth-quarter filing would show the same share counts at a lower price unless the positions changed. For an asset whose investment case has leaned on institutional adoption, the evidence here is participation without accumulation — exposure held, price ignored.